Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BioNeutra Global

TSXV:BGA
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BGA
TSXV
CA$9M
Market Cap
  1. Home
  2. CA
  3. Household
Company description

BioNeutra Global Corporation, through its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages, with a focus on oligosaccharides. The last earnings update was 124 days ago. More info.


Add to Portfolio Compare Print
  • BioNeutra Global has significant price volatility in the past 3 months.
BGA Share Price and Events
7 Day Returns
0%
TSXV:BGA
2.7%
CA Personal Products
6.4%
CA Market
1 Year Returns
-62.3%
TSXV:BGA
-30.5%
CA Personal Products
-25.5%
CA Market
BGA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioNeutra Global (BGA) 0% -4.8% -33.3% -62.3% -57.4% -
CA Personal Products 2.7% -13.1% -18.7% -30.5% -9.9% 6.8%
CA Market 6.4% -22.6% -26.8% -25.5% -23.5% -17.4%
1 Year Return vs Industry and Market
  • BGA underperformed the Personal Products industry which returned -30.5% over the past year.
  • BGA underperformed the Market in Canada which returned -25.5% over the past year.
Price Volatility
BGA
Industry
5yr Volatility vs Market

Value

 Is BioNeutra Global undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioNeutra Global. This is due to cash flow or dividend data being unavailable. The share price is CA$0.2.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioNeutra Global's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioNeutra Global's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:BGA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.11
TSXV:BGA Share Price ** TSXV (2020-03-18) in CAD CA$0.2
North America Personal Products Industry PE Ratio Median Figure of 20 Publicly-Listed Personal Products Companies 11.01x
Canada Market PE Ratio Median Figure of 500 Publicly-Listed Companies 10.58x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioNeutra Global.

TSXV:BGA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:BGA Share Price ÷ EPS (both in CAD)

= 0.2 ÷ -0.11

-1.87x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioNeutra Global is loss making, we can't compare its value to the North America Personal Products industry average.
  • BioNeutra Global is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does BioNeutra Global's expected growth come at a high price?
Raw Data
TSXV:BGA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.87x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Personal Products Industry PEG Ratio Median Figure of 7 Publicly-Listed Personal Products Companies 1.77x
Canada Market PEG Ratio Median Figure of 235 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioNeutra Global, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioNeutra Global's assets?
Raw Data
TSXV:BGA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$0.24
TSXV:BGA Share Price * TSXV (2020-03-18) in CAD CA$0.2
Canada Personal Products Industry PB Ratio Median Figure of 16 Publicly-Listed Personal Products Companies 0.86x
Canada Market PB Ratio Median Figure of 2,349 Publicly-Listed Companies 0.99x
TSXV:BGA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:BGA Share Price ÷ Book Value per Share (both in CAD)

= 0.2 ÷ 0.24

0.85x

* Primary Listing of BioNeutra Global.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioNeutra Global is good value based on assets compared to the CA Personal Products industry average.
X
Value checks
We assess BioNeutra Global's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. BioNeutra Global has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioNeutra Global expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BioNeutra Global has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.2%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioNeutra Global expected to grow at an attractive rate?
  • Unable to compare BioNeutra Global's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare BioNeutra Global's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare BioNeutra Global's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:BGA Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 19.2%
Canada Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 16.1%
Canada Market Earnings Growth Rate Market Cap Weighted Average 7.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:BGA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:BGA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 35 -1 -5
2019-06-30 33 -2 -5
2019-03-31 36 2 0
2018-12-31 38 3 3
2018-09-30 38 6 3
2018-06-30 38 7 2
2018-03-31 35 2 0
2017-12-31 32 2 -1
2017-09-30 31 1 -2
2017-06-30 31 1 -1
2017-03-31 29 1 2
2016-12-31 26 1 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if BioNeutra Global is high growth as no earnings estimate data is available.
  • Unable to determine if BioNeutra Global is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:BGA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from BioNeutra Global Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BGA Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.11
2019-06-30 -0.11
2019-03-31 0.01
2018-12-31 0.07
2018-09-30 0.06
2018-06-30 0.05
2018-03-31 0.01
2017-12-31 -0.03
2017-09-30 -0.04
2017-06-30 -0.02
2017-03-31 0.04
2016-12-31 0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioNeutra Global will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of BGA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. BioNeutra Global's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. BioNeutra Global's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess BioNeutra Global's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioNeutra Global has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioNeutra Global performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioNeutra Global's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioNeutra Global does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioNeutra Global's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioNeutra Global's 1-year growth to the North America Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
BioNeutra Global's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioNeutra Global Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:BGA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 35.31 -4.99 7.81 0.27
2019-06-30 33.32 -4.92 7.77 0.56
2019-03-31 36.49 0.35 7.12 0.47
2018-12-31 37.72 3.10 6.55 0.48
2018-09-30 38.47 2.65 5.71 0.50
2018-06-30 37.95 2.27 5.67 0.30
2018-03-31 34.64 0.35 5.76 0.26
2017-12-31 32.14 -1.16 5.95 0.23
2017-09-30 31.05 -2.04 7.34 0.30
2017-06-30 31.31 -0.81 6.77 0.36
2017-03-31 28.76 1.88 5.87 0.37
2016-12-31 25.99 1.08 4.98 0.39
2016-09-30 23.00 0.84 3.18 0.47
2016-06-30 17.37 0.76 3.16 0.37
2016-03-31 15.29 -0.71 3.75 0.38
2015-12-31 16.04 0.18 4.88 0.40
2015-09-30 18.75 1.20 6.01 0.22
2015-06-30 19.65 1.50 5.66 0.19
2015-03-31 19.86 4.87 4.93 0.18
2014-12-31 15.67 5.11 3.26 0.11
2014-02-28 7.58 0.68 1.70 0.17

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioNeutra Global has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if BioNeutra Global has efficiently used its assets last year compared to the North America Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if BioNeutra Global improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioNeutra Global's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioNeutra Global has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioNeutra Global's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioNeutra Global's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioNeutra Global is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioNeutra Global's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioNeutra Global's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioNeutra Global Company Filings, last reported 6 months ago.

TSXV:BGA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 10.97 8.30 1.82
2019-06-30 12.37 8.51 1.49
2019-03-31 16.84 8.72 1.61
2018-12-31 18.06 8.94 1.50
2018-09-30 15.65 9.15 3.84
2018-06-30 16.76 9.84 5.00
2018-03-31 15.92 9.79 0.59
2017-12-31 13.96 10.01 1.39
2017-09-30 12.71 9.57 1.05
2017-06-30 14.38 9.86 1.32
2017-03-31 15.78 10.15 0.69
2016-12-31 15.78 9.88 0.59
2016-09-30 15.20 9.77 1.90
2016-06-30 15.11 8.95 2.25
2016-03-31 13.74 8.94 2.13
2015-12-31 15.19 8.95 1.63
2015-09-30 14.69 7.57 2.06
2015-06-30 12.98 0.45 4.19
2015-03-31 13.01 0.45 5.23
2014-12-31 10.64 0.29 2.08
2014-02-28 1.93 0.00 1.19
  • BioNeutra Global's level of debt (75.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (2.6% vs 75.6% today).
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on BioNeutra Global's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess BioNeutra Global's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioNeutra Global has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioNeutra Global's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioNeutra Global dividends.
If you bought CA$2,000 of BioNeutra Global shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioNeutra Global's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioNeutra Global's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:BGA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.9%
Canada Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 4.9%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.3%
Canada Bottom 25% Dividend Yield 25th Percentile 2.7%
Canada Top 25% Dividend Yield 75th Percentile 8.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioNeutra Global has not reported any payouts.
  • Unable to verify if BioNeutra Global's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioNeutra Global's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioNeutra Global has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioNeutra Global's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioNeutra Global afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioNeutra Global has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioNeutra Global's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jianhua Zhu
COMPENSATION CA$187,952
TENURE AS CEO 5.4 years
CEO Bio

Dr. Jianhua Zhu, Ph.D., is Founder and has been Chief Executive Officer of BioNeutra Global Corporation since October 2014 and serves as its President. Dr. Zhu has been Chief Executive Officer and Director of BioNeutra North America Inc. since 2003 and serves as its President. He has been a Director of BioNeutra Global Corporation since October 29, 2014. He is a Director of BioNeutra International Limited since 2004. He is a co-owner at Manlog Investments Limited.

CEO Compensation
  • Jianhua's compensation has increased whilst company is loss making.
  • Jianhua's remuneration is about average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the BioNeutra Global management team in years:

1.8
Average Tenure
  • The average tenure for the BioNeutra Global management team is less than 2 years, this suggests a new team.
Management Team

Bill Smith

TITLE
Chairman of the Board of Directors & Senior VP
COMPENSATION
CA$163K

Jianhua Zhu

TITLE
Founder
COMPENSATION
CA$188K
TENURE
5.4 yrs

Yiyuan Jiang

TITLE
Acting Chief Financial Officer

Warren Michaels

TITLE
Vice-President of Communications & HR
TENURE
1.8 yrs

Sheri O'Brien

TITLE
Vice President of Sales & Marketing
TENURE
1.2 yrs

Monica Barclay

TITLE
Corporate Secretary
Board of Directors Tenure

Average tenure of the BioNeutra Global board of directors in years:

0.6
Average Tenure
  • The average tenure for the BioNeutra Global board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bill Smith

TITLE
Chairman of the Board of Directors & Senior VP
COMPENSATION
CA$163K
TENURE
0.3 yrs

Jianhua Zhu

TITLE
Founder
COMPENSATION
CA$188K
TENURE
5.4 yrs

Bill Cheung

TITLE
Independent Director
COMPENSATION
CA$66K
TENURE
0.6 yrs

William Wei

TITLE
Director
TENURE
0.6 yrs

Jason Theiss

TITLE
Director
TENURE
0.6 yrs

Curtis Sparrow

TITLE
Director
AGE
62
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • BioNeutra Global individual insiders have only sold shares in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
02. Jan 20 Sell Douglas Horner Individual 31. Dec 19 31. Dec 19 -10,000 CA$0.30 CA$-3,000
17. Dec 19 Buy Monica Barclay Individual 04. Dec 19 04. Dec 19 16,000 CA$0.26 CA$4,160
X
Management checks
We assess BioNeutra Global's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioNeutra Global has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Read This Before Judging BioNeutra Global Corporation's (CVE:BGA) ROE

The formula for ROE is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for BioNeutra Global: 2.1% = CA$347k ÷ CA$17m (Based on the trailing twelve months to March 2019.) Most readers would understand what net profit is, but it’s worth explaining the concept of shareholders’ equity. … Does BioNeutra Global Have A Good Return On Equity? … Combining BioNeutra Global's Debt And Its 2.1% Return On Equity Although BioNeutra Global does use debt, its debt to equity ratio of 0.52 is still low.

Simply Wall St -

Should We Worry About BioNeutra Global Corporation's (CVE:BGA) P/E Ratio?

Check out our latest analysis for BioNeutra Global How Do I Calculate A Price To Earnings Ratio? … The formula for P/E is: Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS) Or for BioNeutra Global: P/E of 53.68 = CA$0.41 ÷ CA$0.0075 (Based on the trailing twelve months to March 2019.) Is A High P/E Ratio Good? … The Bottom Line On BioNeutra Global's P/E Ratio With a P/E ratio of 53.7, BioNeutra Global is expected to grow earnings very strongly in the years to come.

Simply Wall St -

We Think BioNeutra Global (CVE:BGA) In Taking Some Risk With Its Debt

TSXV:BGA Historical Debt, July 4th 2019 A Look At BioNeutra Global's Liabilities Zooming in on the latest balance sheet data, we can see that BioNeutra Global had liabilities of CA$13.6m due within 12 months and liabilities of CA$7.77m due beyond that. … In the last three years, BioNeutra Global created free cash flow amounting to 15% of its EBIT, an uninspiring performance. … Our View Neither BioNeutra Global's ability to cover its interest expense with its EBIT nor its conversion of EBIT to free cash flow gave us confidence in its ability to take on more debt.

Simply Wall St -

What You Should Know About BioNeutra Global Corporation's (CVE:BGA) Financial Strength

Additionally, BGA has generated cash from operations of CA$2.4m over the same time period, resulting in an operating cash to total debt ratio of 28%, indicating that BGA’s debt is appropriately covered by operating cash. … Looking at BGA’s CA$14m in current liabilities, it appears that the company has been able to meet these commitments with a current assets level of CA$22m, leading to a 1.64x current account ratio. … Next Steps: BGA’s high cash coverage means that, although its debt levels are high, the company is able to utilise its borrowings efficiently in order to generate cash flow.

Simply Wall St -

Shareholders Should Look Hard At BioNeutra Global Corporation’s (CVE:BGA) 9.2% Return On Capital

The formula for calculating the return on capital employed is: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) Or for BioNeutra Global: 0.092 = CA$2.4m ÷ (CA$40m - CA$14m) (Based on the trailing twelve months to December 2018.) So, BioNeutra Global has an ROCE of 9.2%. … What Are Current Liabilities, And How Do They Affect BioNeutra Global's ROCE? … Due to the way ROCE is calculated, a high level of current liabilities makes a company look as though it has less capital employed, and thus can (sometimes unfairly) boost the ROCE.

Simply Wall St -

Is BioNeutra Global Corporation's (CVE:BGA) 17% ROE Strong Compared To Its Industry?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows BioNeutra Global has a return on equity of 17% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Can You Imagine How BioNeutra Global's (CVE:BGA) Shareholders Feel About The 33% Share Price Increase?

To wit, the BioNeutra Global Corporation (CVE:BGA) share price is 33% higher than it was a year ago, much better than the market return of around 0.02% (not including dividends) in the same period. … During the last year BioNeutra Global grew its earnings per share, moving from a loss to a profit. … When a company is just on the edge of profitability it can be well worth considering other metrics in order to more precisely gauge growth (and therefore understand share price movements).

Simply Wall St -

Why BioNeutra Global Corporation’s (CVE:BGA) Use Of Investor Capital Doesn’t Look Great

Specifically, we'll consider its Return On Capital Employed (ROCE), since that will give us an insight into how efficiently the business can generate profits from the capital it requires. … Return On Capital Employed (ROCE): What is it? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

BioNeutra Global Corporation (CVE:BGA) Has A ROE Of 17%

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows BioNeutra Global has a return on equity of 17% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

How Financially Strong Is BioNeutra Global Corporation (CVE:BGA)?

While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Evaluating financial health as part of your investment thesis is. … Here are few basic financial health checks you should consider before taking the plunge.

Simply Wall St -

Company Info

Description

BioNeutra Global Corporation, through its subsidiaries, engages in the research and development, production, and commercialization of food ingredients for nutraceutical, functional, and mainstream foods and beverages, with a focus on oligosaccharides. Its lead product is VitaFiber, an isomalto-oligosaccharide functional and health food ingredient that offers low calorie and soluble fiber for human digestive health. The company serves small and medium enterprises, and various food and beverage manufacturers in Canada, the United States, Europe, Australia, New Zealand, South East Asia, and the United Kingdom. It also provides VitaFiber through Amazon.com and Shopify.com, as well as other direct-to-consumer retailers. The company was formerly known as Intercap eCommerce Inc. and changed its name to BioNeutra Global Corporation in October 2014. BioNeutra Global Corporation is based in Edmonton, Canada.

Details
Name: BioNeutra Global Corporation
BGA
Exchange: TSXV
Founded:
CA$9,163,957
45,819,787
Website: http://www.bioneutra.ca
Address: BioNeutra Global Corporation
9608-25 Avenue NW,
Edmonton,
Alberta, T6N 1J4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV BGA Common Shares TSX Venture Exchange CA CAD 23. Oct 2015
Number of employees
Current staff
Staff numbers
19
BioNeutra Global employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 02:59
End of day share price update: 2020/03/18 00:00
Last earnings filing: 2019/11/27
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.